trending Market Intelligence /marketintelligence/en/news-insights/trending/39nniWbevCbortB4VUfVjQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Credit Suisse thinks Greenhill headed for earnings pressure

Street Talk Episode 68 - As many investors zig away from bank stocks, 2 vets in the space zag toward them

Street Talk Episode 66 - Community banks tap the debt markets while the getting is good

Street Talk Episode 67 - Veteran investor tabs Mick Mulvaney to help with latest financial stock-focused fund

Street Talk Episode 65 - Deferral practices trap US bank portfolios in purgatory

Credit Suisse thinks Greenhill headed for earnings pressure

Credit Suisse analyst Ashley Serrao thinks macro conditionspoint to an M&A lull that will favor investment bankers with a strong anddiverse backlog of advisory fees. Greenhill & Co.Inc.'s backlog is concentrated around one acquisition, and based onhis economic forecast, the analyst downgraded the company to"underperform" from "neutral."

Serrao noted that 31% of Greenhill's enhanced backlog isrelated to their service in Teva Pharmaceutical Industries Ltd.'s deal toacquire Allergan Generics, leaving about $50 million in revenues for Greenhillto replace during what the analyst thinks will be a quiet second half in dealsfor 2016.

The bank's advisory announcements this year have lagged itspeers, amplifying the backlog risk and pressuring 2017 revenues, Serrao wrote.Greenhill has cash warehoused overseas for tax reasons and has increased itscredit facility to meet substantial payment obligations in the U.S. thatincludes paying down debt from the acquisition of Cogent Partners LP and funding dividendand bonus payments.

"But this all comes at the cost of share countcreep," Serrao said, adding that he incorporated that dilution into hisestimates.

Serrao's target price for Greenhill is $13. He lowered hissecond-quarter EPS estimate to 37 cents from 70 cents. He held his 2016 fiscalyear EPS estimate at $1.33 but lowered his 2017 estimate to $1.07 from $1.15.For 2018, Serrao raised his estimate to $1.24 per share from $1.02 per share.